Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | CDC25A | P30304 | 2/20 | 0.54 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18850564 | 0.86 | NR1H4 (0.49) | VDRUSP2CDC25A | |
| SCHEMBL19413532 | 0.86 | NR1H4 (0.49) | VDRUSP2CDC25A | |
| SCHEMBL6363543 | 0.84 | VDR (0.74) | VDRUSP2CDC25AST6GAL1ALDH1A1 | |
| SCHEMBL22837114 | 0.81 | NR1H4 (0.57) | — | |
| SCHEMBL21163766 | 0.81 | NR1H4 (0.57) | — | |
| SCHEMBL21163755 | 0.81 | NR1H4 (0.57) | — | |
| SCHEMBL15700227 | 0.81 | NR1H4 (0.57) | — | |
| SCHEMBL18850503 | 0.81 | NR1H4 (0.57) | — | |
| SCHEMBL18850504 | 0.81 | NR1H4 (0.57) | — | |
| SCHEMBL18848976 | 0.81 | NR1H4 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202414-B2 | Process for preparing bile acid derivatives | INTERCEPT PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202414-B2 | Process for preparing bile acid derivatives | NR1H4, SLC10A1, CYP7A1 | VDR 1812/4885USP2 3847/4885CDC25A 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.